TALK ABOUT US IN...

"5 of our portfolio companies included by Seedtable among the most promising deep tech startups in our ecosystem for this 2023"

"The award for innovation in wellness , has been awarded to Cuideo, for its commitment to helping families care for the elderly and dependent people at home."

"Spanish startup Airway Shield, specializing in medical devices, has won the competition for best startup project in the Health category of the South Summit Brazil 2023 international competition."

"The Spanish company captures this investment from the Diagnostics Accelerator of the Alzheimer's Drug Discovery Foundation, which will help it in the clinical validation and regulatory approval of its technology."

"Lung cancer is the fourth leading cause of death worldwide and 47% of patients diagnosed with the disease may not be receiving the most appropriate treatment.

These are data from the clinical study conducted by the Basque company, Hawk Biosystems, which has just been published by the most prestigious international scientific journal in the field of cancer, the American "Journal of Clinical Oncology" (JCO).

"Vytrus Biotech, a company specializing in plant stem cell-derived active ingredients for the cosmetics industry, has had a 98% revaluation in 2022."

"^PreveCol® the blood test for AMADIX for the early detection of colorectal cancer is now available at the Hyper Early Diagnosis office in the hospitals of the HM Hospitales Group.

Et is indicated for the early detection of colorectal cancer and/or precancerous lesions in asymptomatic individuals between 50 and 75 years of age. "

" Dr. José Manuel Soria, MD, has published in the most important scientific journal in the world of oncology, Journal of Clinical Oncology, a study on a new tool for the prediction of thrombosis in oncology patients.

The tool, called ONCOTHROMB, combines clinical and genomic patient data, and has demonstrated excellent predictive capacity; it has the ability to identify 34% of patients who will suffer a thromboembolic event and 94% of patients who do not need treatment with anticoagulants.

This study pioneers the application of genetics in the measurement of thrombosis risk in cancer."

"Arjuna Therapeutics has been selected among the best tech startups globally, and is featured in Hello Tomorrow's Medical and Pharmaceutical Biotechnology category, which has compiled a ranking of finalists engaged in developing disruptive innovations from across industries."

"The biotech company Ability Pharma has begun preparations to go public. The company led by Carles Domènech does not have an exact date to join one of Euronext's alternative markets, but wants to be readyto do so when the economic scenario is favorable, market sources say. "

"Devicare reports the launch of Methiophytin®; the only product on the market that allows acidifying urine to maximize the efficacy of antibiotics by increasing the concentration of their bioactive form.

With Metiofitin® you can reduce urinary tract infections more effectively and/or reduce the amount of antibiotic needed to achieve this. It is the result of years of research in collaboration with urologists throughout Spain."

"The test to be used in Spain for kidney transplant recipients represents a breakthrough in personalized medicine. This new healthcare approach, for which the Government has just announced an investment of 40 million euros to deploy in the autonomous communities the so-called 5P Plan, which aims to use devices such as the one proposed by Biohope. With uses such as this device, it will be possible to choose the most appropriate treatment and reduce failures."

"The European Innovation Council is awarding this grant to the company, although the company may be eligible for up to fifteen million euros of investment through the EIC Fund. The resources will allow the company to continue developing its artificial intelligence (AI) system against stroke, generate more scientific evidence and help bring the product to market. "There are very disruptive technologies, but there is no venture capital for such disruptive projects," as the executive explains."

"Neuraxpharm Group, a leading European pharmaceutical company specializing in the treatment of Central Nervous System (CNS) disorders, and mjn-neuro, a start-up that designs, produces and sells medical devices, have announced the signing of a commercialization agreement for mjn-SERAS, a wearable medical device that can predict the risk of suffering an epileptic seizure."

"Devicare, a company located at the UAB Research Park, launches Canoxidin®, the only product on the market that prevents complications from the use of urological devices, such as bladder catheters, ureteral catheters or nephrostomy tubes."

"The Spanish biotech firm has signed an agreement with the hospital operator under which the latter will now offer 24Genetics' genetic tests. In addition, the company has started operations in Boston (USA). "

" The Agreement values Ducentis at up to $400 million, including upfront cash payment of $16 million and Arcutis stock valued at about $14 million, plus future contingent payments based on development and commercial success. "

"Chosen by the Forbes list as a Protagonist of Change in 2022, distinguished for her career as a scientist, researcher and entrepreneur in the prevention and early detection of cancer."

"The startup Corify Care has won the EmprendeXXI Awards in Madrid, promoted by CaixaBank, through DayOne, its specialized division for technology and innovation companies and their investors, and co-sponsored by the Ministry of Industry, Trade and Tourism, through ENISA. In Madrid, the organization of the EmprendeXXI Awards is supported by the Madrid Chamber of Commerce and the Madrid+d Foundation."

"Oculis, a global ophthalmology company, announced on March 2, 2022 that it has formed a licensing agreement with Accure Therapeutics, a private translational neuroscience R&D company, granting Oculis exclusive global rights to develop and commercialize ACT-01, a drug candidate for glaucoma and other eye diseases."

"Capital Cell, an online investment platform specializing in biotechnology and healthcare, has closed 2021 with more than €19 million in capital raised for this type of companies. This figure is 39% more than in 2020 and represents a new record for Capital Cell, which during last year closed financing rounds for 19 companies. The crowdfunding platform has participated since its birth in 2015 in 67 financing rounds for a total amount of €59 million."

"The Barcelona-based startup of digital technology solutions for allergoprotection will open a financing round to raise one million euros to start marketing boxes containing adrenaline that can be installed in public spaces to tackle severe allergic reactions, cases of anaphylaxis."

"Over the past decade, crowdfunding has become a popular way to finance all kinds of projects and products. Biotech is no exception, but many question whether the high risk and long-term nature of investing in the biotech industry makes it suitable for equity crowdfunding."

"Investment in biotechnology is more profitable than real estate and the Internet, and onlinecrowfunding companies allow private investors to access these types of assets. In Spain we have very interesting technologies and we are making a really spectacular portfolio of investments through Spanish companies with high potential"

"The goal is to create this 'marketplace' in which Capital Cell will be responsible for analyzing and filtering the best investment opportunities."

"We have been studying blockchain technology for six months now and it has become clear to us that our goals are best achieved with an ICO ( initial coin offering)."

"Gambling to determine whether contributing to saving lives can also become a profitable, sustainable business model and above all, focusing the primary focus on patients."

"The biomedical start-up investment platform is supported by a global network of experts who assess the technical feasibility of the initiatives." 

"SMEs and start-ups are the main users of new crowdfunding tools."

"From 2002 to 2015, the IBB Nasdaq index, which groups these types of companies, has accumulated a return of 448% compared to 235% for the S&P 500."

"The CEO of Capital Cell, Daniel Oliver, has advanced that he will locate the headquarters of this subsidiary in Cambridge, "which is the most important hub in Europe in biotechnology," he said."

"The Catalan company, creator of a device to improve the prognosis of ischemic stroke, will receive 3.3 million from the EIC Accelerator program."

"The University of the Balearic Islands and the company Devicare bring to market the compound Canoxidin, which avoids complications in the use of catheters and probes"

"Asisa highlights that it has more than 2.8 million policyholders to whom it offers a wide range of healthcare coverage, both face-to-face and remote. "The alliance with mediQuo will allow Asisa to advance in its bid to position itself as a leading insurance company also in telemedicine," says the company."

"VB Devices and Cardiva have announced this Monday that the latter will assume the exclusive distribution of Varixio in Spain, giving continuity to the commercialization started by VB Devices itself in 2021."

"Glycoscience announces that they have been approved by France as the first country in which they will market Glyco-Protec®. It is the best topical insect repellent in the world, thanks to its natural, non-toxic components and its high level of efficacy, superior to anything known until now. It is also the first in a range of repellents with improved characteristics that will redefine the world market for this type of product.

In parallel, Glycoscience reports that it has started industrial production activities. "

"The system, developed by ADmit Therapeutics, is expected to reach the market by the end of this year and will represent a giant step forward in the fight against Alzheimer's disease. "

"The Spanish company, which has created a medical device for improving the prognosis of ischemic stroke, hopes to begin commercial activity in Europe once it completes clinical validation studies.

The Spanish company will receive 5.8 million euros from the European Commission, through the European Innovation Council (EIC) accelerator. This aid will enable progress to be made in the company's strategic plan for the coming years."

"Vytrus Biotech, a company specializing in plant stem cell-derived active ingredients for the cosmetic industry, has announced that it has obtained approval of its first patent for the prevention and treatment of hair loss in Europe, the United States and Japan."

"The Ministry of Science and Innovation, through the State Plan for Scientific Research, will inject 2.4 million euros into Oxolife to carry out a clinical trial for a new treatment against infertility in cases of Polycystic Ovary Syndrome.
The trial will be conducted together with the University of Cordoba and represents a huge boost for the company's product portfolio. "

" The co-founder and CEO of the company FrontWave Imaging, Susana Castel, has been chosen by the university EAE Business School of Barcelona the first among the 10 best women entrepreneurs in Catalonia. "

"Thus, this animal health firm has incorporated the ingredient developed by AntalGenics into its new product line, creating a topical solution to treat the skin of animals prone to dermatitis."

"Biohope is the first Spanish biotech to win the Lyfebulb-Veloxis Innovation Challenge award in the United States, for its novel IVD Kit called Immunobiogram®, which allows physicians to optimize immunosuppressive therapy in kidney transplant patients."

"The Pre-Market Environment (EpM), BME's acceleration programme within the process of incorporating companies into the financial markets, has grown with the incorporation today of the companies Onalabs, Ludium, Vamos and V2C. The program now comprises 24 companies."

"The winning formulation of Vytrus (Purple Rain : Microbiota re-youth peel-off mask), is an innovative, effective and sustainable mask thanks to the careful choice of all its components, from the ingredients to the packaging."

"The Catalan company has received the amount as non-dilutive funding from the Ministry of Science and Innovation to accelerate the regulatory pathway for its anti-cancer autophagy indicator ABTL0812, adds Domènech. The drug has been shown to be able to induce cancer cell death through autophagy (self-digestion)."

"Hipra has closed the acquisition, announced in August, of biotechnology startup GoodgutThe acquisition of the biotech startup, specialized in the research and development of diagnostic tests for digestive diseases, was announced in August. The objective of this operation is to strengthen the Human Health division of the Girona-based pharmaceutical company."

"The U.S. Food and Drug Administration (FDA) has granted fast-track designation to the molecule LAM561, developed by the Majorcan company Laminar Pharmaceutical to fight glioblastoma, an aggressive type of cancer that is generated in the brain or spinal cord and has a very high mortality rate within a few months of diagnosis."

"Inderhabs Investments -from investor Pere Botet- and Mundi Ventures also participated in the Series B round. The Barcelona-based startup of home care for the elderly plans to accelerate its implementation in France and is negotiating agreements to develop hand in hand with insurance companies."

"For its creation, Accure Therapeutics has completed a €7.6 million investment round that will allow it to develop its product portfolio and acquire Iproteos and Bionure - a company specialized in the development of neuroprotective agents, based at the Parc Científic de Barcelona. The investment round has been led by Alta Life Sciences and has been supported by the Center for Technological and Industrial Development (CDTI)."

"The biotech, founded by Albert Jané and Oscar Expósito, who control 40% of the share capital, has a 33% free float, shares distributed among 262 small investors who largely entered a crowfunding operation led by Capital Cell in 2017, and who have multiplied the value of their investment in the company."

"The social scope of each of the projects and their impact on making the work of medical professionals easier, as well as their innovative nature and their scientific and clinical evidence were some of the jury's determining criteria for selecting the winners."

"The company has obtained the 320,000 euros it was asking for through the Barcelona-based equity crowdfunding platform in a very short time, becoming the third company to achieve this, after the success stories of Corify and Time is Brain."

"It turns out that the pandemic has made it clear that we need science, innovation and research, were we in the right place at the right time? Yes, but because at the time we made a courageous and tremendously logical bet to look to the future and think long term."

"Capital Cell, Europe's first online investment platform specialized in biotechnology and medicine, has raised €700,000 in its third round of funding, the target set, although it will be open to new investors until it reaches €1.1 million."

"Capital Cell has raised 100% of its planned capital in four days, money that will go toward creating the first initial coin offering (ICO) marketplace in healthcare using blockchain technology, it said in a statement today."

"We will see applications that will allow patient-controlled access and distribution of their data with blockchain, these will represent a revolution in the use of medical resources and their management."

"There are more cancer solutions than we realize that stay inside a box and don't make it to market because of a lack of financial liquidity."

"There is a lack of capital to get knowledge out of hospitals and universities that in the end does not reach the market as a treatment. Many physicians have databases of countless patients that well linked could help create products to improve diagnostics. Crowdfunding is an effective way to bring cancer products to market."

"Capital Cell expects to close the year with €4.8 million raised in Spain and the United Kingdom, representing a 44% increase in financing volume compared to 2016"

"Through equity crowdfunding we have created a marketplace where anyone can invest today in the pharmaceutical companies of tomorrow. We are very pleased that Capital Cell 's activity has taken off so quickly and has had this incredible reception."